Street View: Line-up of key launches to drive US sales growth for India's Cipla

Cipla

28/07/2025 06:56

** India's third-largest drugmaker by sales, Cipla CIPL.NS reported quarterly profit that beat analysts' estimates on higher domestic demand for its generic respiratory drugs

** Shares climbed 2% on the day after rising about 3% post results on Friday

** At least 14 brokerages hiked price targets on the stock after earnings, raising the median PT to 1,723.5 rupees from 1,675 rupees last month, as per data compiled by LSEG

LINE-UP OF KEY LAUNCHES IN THE U.S. TO DRIVE GROWTH

** HSBC ("buy," PT: 1,740 rupees) says decline in Cipla's sales of generic cancer drug gRevlimid is imminent in FY26

** Adds, a good line-up of differentiated launches in the U.S. likely to offset the weakness

** Goldman Sachs ("sell," PT: 1,375 rupees) expects Cipla to rely heavily on new launches for growth in the United States

** Jefferies ("hold," PT: 1,690 rupees) says growth in key U.S. market disappointed, but launches in the market will start reflecting in Cipla's growth from H2FY27 onwards

 (Reporting by Manvi Pant in Bengaluru)

 ((Manvi.Pant@thomsonreuters.com; +918447554364;))